9 unknown, 8 completed, 3 terminated, 1 recruiting. 22 Phase 2, 8 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 22 | Unknown 9, Completed 8, Terminated 3, Recruiting 1, Withdrawn 1 |
| Phase 3 | 8 | Unknown 5, Terminated 2, Completed 1 |
| Phase 1 | 1 | Completed 1 |
Follow COVID 19: new trials by email Literature Review of COVID 19 trials Research Report on COVID 19
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Community-based Behavioral Intervention to Increase Vaccination Using MOST Health education on COVID and flu vaccination, Nurse-led shared decision-making, Text messages - COVID 19, Influenza | Phase 2 | Withdrawn | New York University | 2025-04-01 | 2025-04-29 | |
| COVID-19 Booster and IIV Schedule in Immunocompromised Hosts Inactivated influenza vaccine (IIV) at baseline, COVID-19 Vaccines at a 3-month interval, Inactivated influenza vaccine at Month 1 - COVID 19, Influenza | Phase 2 | Recruiting | McGill University Health Centre/Research Institute of the McGill University Health Centre | 660 | 2024-11-20 | 2026-10-26 |
| Colostrum From MERS-CoV Seropositive Camels for SARS-CoV-2 Infection - a Placebo-controlled Randomized Trial. Colostrum Nasal Spray, Water for injection - COVID 19 | Phase 1 / Phase 2 | Completed | Hadassah Medical Organization | 43 | 2023-05-01 | 2025-03-04 |
| Allogenic UCMSCs as Adjuvant Therapy for Severe COVID-19 Patients Normoxic Allogenic UCMSC, Normal saline solution - Covid 19 | Phase 2 / Phase 3 | Unknown | Kementerian Riset dan Teknologi / Badan Riset dan Inovasi Nasional, Indonesia | 42 | 2021-01-17 | 2021-11-24 |
| Low Dose of IL-2 In Acute Respiratory DistrEss Syndrome Related to COVID-19 1: ILT101, 2: Placebo Comparator - COVID 19 | Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 30 | 2020-10-23 | 2021-10-04 |
| Inhaled Ciclesonide for Outpatients With COVID19 Normal Saline intranasal and placebo inhaler, Ciclesonide, Ciclesonide nasal - COVID 19 | Phase 2 / Phase 3 | Terminated | McGill University Health Centre/Research Institute of the McGill University Health Centre | 215 | 2020-09-15 | 2022-06-10 |
| Post Exposure Prophylaxis in Healthcare Workers Exposed to COVID-19 Patients Hydroxychloroquine - COVID 19 | Phase 2 / Phase 3 | Unknown | Hamad Medical Corporation | 500 | 2020-08-31 | 2020-08-11 |
| Efficacy and Safety of Sirolimus in COVID-19 Infection Sirolimus - COVID 19 | Phase 2 | Unknown | Alexandria University | 40 | 2020-08-15 | 2020-09-09 |
| Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS). Pemziviptadil (PB1046), Low Dose (10 mg) Control - Acute Respiratory Distress Syndrome, Coronavirus | Phase 2 | Terminated | PhaseBio Pharmaceuticals Inc. | 54 | 2020-07-15 | 2020-12-11 |
| IMU-838 and Oseltamivir in the Treatment of COVID-19 IMU-838, Oseltamivir - Covid 19 | Phase 2 | Completed | University Hospitals Coventry and Warwickshire NHS Trust | 38 | 2020-06-15 | 2023-08-22 |
| Potential Role of Gum Arabic as Immunomodulatory Agent Among COVID 19 Patients Acacia Senegal, Pectin - COVID 19 | Phase 2 / Phase 3 | Unknown | Al-Neelain University | 110 | 2020-06-01 | 2020-05-12 |
| Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation Mavrilimumab, Placebo - COVID 19, SARS-CoV 2 | Phase 2 | Completed | Kristin Hudock | 1 | 2020-05-20 | 2024-12-09 |
| Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation Mavrilimumab, Placebos - COVID 19, SARS-CoV 2 | Phase 2 | Completed | The Cleveland Clinic | 40 | 2020-05-20 | 2021-05-13 |
| Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications Convalescent Plasma, Standard Care Therapy - COVID 19 | Phase 2 | Unknown | Max Healthcare Insititute Limited | 100 | 2020-05-09 | 2020-07-22 |
| COLchicine Versus Ruxolitinib and Secukinumab in Open-label Prospective Randomized Trial in Patients With COVID-19 Colchicine, Ruxolitinib 5 MG, Secukinumab 150 MG/ML Subcutaneous Solution [COSENTYX] - COVID 19 | Phase 2 | Completed | Lomonosov Moscow State University Medical Research and Educational Center | 70 | 2020-05-08 | 2022-11-25 |
| Efficacy of Various Doses of Hydroxychloroquine in Pre-Exposure Prophylaxis for COVID 19 Hydroxychloroquine Sulfate 200 MG, Placebo - COVID 19 | Phase 2 | Unknown | Shaheed Zulfiqar Ali Bhutto Medical University | 200 | 2020-05-01 | 2020-05-19 |
| Mesenchymal Stem Cell for Acute Respiratory Distress Syndrome Due for COVID-19 Infusion IV of Mesenchymal Stem cells - Covid 19 | Phase 2 | Unknown | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | 10 | 2020-05-01 | 2020-06-04 |
| Trial of Hydroxychloroquine In Covid-19 Kinetics Hydroxychloroquine, Placebo - Covid 19, Corona Virus Infection | Phase 2 / Phase 3 | Terminated | University of South Alabama | 3 | 2020-04-17 | 2022-01-03 |
| Oral 25-hydroxyvitamin D3 and COVID-19 Oral 25-Hydroxyvitamin D3 - COVID 19 | Phase 2 / Phase 3 | Unknown | Tehran University of Medical Sciences | 1500 | 2020-04-14 | 2020-06-12 |
| A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection Fluvoxamine, Placebo - COVID 19, Coronavirus | Phase 2 | Completed | Washington University School of Medicine | 152 | 2020-04-10 | 2021-07-09 |
Showing 20 of 22. Sign in to see all of them.
COVID-19 (22) · Coronavirus Infections (3) · Pneumonia (3) · Cytokine Release Syndrome (2) · Influenza, Human (2) · Respiratory Distress Syndrome (2) · Arthritis, Rheumatoid (1) · Cardiovascular Diseases (1) · Dyspnea (1) · Heart Failure (1) · Inflammatory Bowel Diseases (1) · Myocardial Infarction (1) · Pulmonary Edema (1) · Respiratory Insufficiency (1) · Severe Acute Respiratory Syndrome (1)
Coronaviridae Infections (22) · Infections (22) · Lung Diseases (22) · Nidovirales Infections (22) · Pneumonia, Viral (22) · RNA Virus Infections (22) · Respiratory Tract Diseases (22) · Respiratory Tract Infections (22) · Virus Diseases (21) · Coronavirus Infections (19) · Pneumonia (19) · Inflammation (2) · Orthomyxoviridae Infections (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2)
Hydroxychloroquine (4) · Standard of Care (2) · mavrilimumab (2) · Calcifediol (1) · Colchicine (1) · Fluvoxamine (1) · Gum Arabic (1) · Influenza Vaccines (1) · Injections (1) · Oseltamivir (1) · Pectins (1) · Saline Solution (1) · Sirolimus (1) · VIP-ELP fusion molecule PB1046 (1) · Vaccination (1)
McGill University Health Centre/Research Institute of the McGill University Health Centre (2) · Al-Neelain University (1) · Alexandria University (1) · Assistance Publique - Hôpitaux de Paris (1) · Hadassah Medical Organization (1) · Hamad Medical Corporation (1) · Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran (1) · Kementerian Riset dan Teknologi / Badan Riset dan Inovasi Nasional, Indonesia (1) · Kristin Hudock (1) · Lomonosov Moscow State University Medical Research and Educational Center (1) · Materno-Perinatal Hospital of the State of Mexico (1) · Max Healthcare Insititute Limited (1) · New York University (1) · Oslo University Hospital (1) · PhaseBio Pharmaceuticals Inc. (1)
United States (5) · Canada (2) · Mexico (2) · Egypt (1) · France (1) · India (1) · Indonesia (1) · Iran (1) · Israel (1) · Norway (1) · Pakistan (1) · Russia (1) · Sudan (1) · United Kingdom (1)
Ahmad Faried, Prof. MD (1) · Andreas Barratt-Due, MD, PhD (1) · Anne Margarita Dyrhol Riise, MD, Professor (1) · Arash Shirvani, MD, PhD (1) · Arief Nurudin, MD PhD (1) · Ayman I Baess, MD (1) · Eric J Lenze, MD (1) · Fibhaa Syed, FRCP (1) · Inge Christoffer Olsen, PhD (1) · Katerina Nezvalova-Henriksen, Pharm D, PhD (1) · Kristin Hudock, MD (1)
PMID 33754144, PMID 29859173, PMID 32085846, PMID 32214286, PMID 32265310, PMID 32281062, PMID 32756149, PMID 32891160, PMID 33180097, PMID 33240091, PMID 33757717, PMID 34251903, PMID 34350582, PMID 34658014, PMID 34728476, PMID 35876699, PMID 36396307, PMID 36695483, PMID 39533001, PMID 40329764
2025 (1)